Insulinepen vialAlso known as: 3 ml Insulinepen vial, Insulinepen vial 3ml

Mechanism of Action

Not applicable, since this product is a device (vial) designed for administration and storage of peptides in research settings, rather than a biochemical agent.

Reported Research Benefits

Used for precise and sterile dosing of peptides such as BPC-157 in laboratory and research environments. Compatible with insulin pens for peptides requiring small volume delivery.

Dosing Protocol & Reconstitution

Not applicable to the vial itself. Dosing depends on the peptide administered through the vial; the vial has a 3 ml capacity suitable for one-time use with insulinepens.

Research Notes

Provides sterile, single-use containment and administration of peptides like BPC-157, supporting reproducible laboratory peptide dosing and reducing contamination risk.

Research Summary

The Insulinepen vial is not a peptide itself but a delivery and storage device commonly used for administering insulin and other peptide-based therapeutics in clinical and research settings. While there are no direct studies on the vial itself, ample high-quality clinical evidence supports the efficacy and safety of insulin administration using pen devices, which improve dosing accuracy, patient compliance, and convenience compared to traditional syringe methods. The device facilitates precise peptide delivery in human subjects, largely supported by randomized controlled trials and observational studies focusing on insulin therapy in diabetes management. Limitations include device-related mechanical failures and user errors rather than biochemical effects.

Side Effects & Safety

As a non-pharmacological device, the Insulinepen vial does not itself cause biochemical side effects. However, safety considerations relate to device sterility, proper storage conditions, and correct usage to minimize risks such as insulin degradation, contamination, or inaccurate dosing. Potential adverse effects stem from insulin administration errors, including hypoglycemia or injection site reactions. There is no direct animal evidence related to the device, but clinical guidelines emphasize using single-use needles and regular inspection of the device. The device itself is not subject to WADA restrictions, but the contained peptide (e.g., insulin) may be regulated depending on the context.

Stability & Storage

Refer to research notes

Molecular Data

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=Insulinepen+vial